Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Biogen Inc (BIIB) vs DexCom, Inc. (DXCM) Price & Performance

Biogen IncTrade
DexCom, Inc.Trade

Price performance (Past 24H)

Key statistics

Biogen Inc vs DexCom, Inc. — how do they compare? Biogen Inc trades at $204.1 (market cap $30.13B), while DexCom, Inc. trades at $88.22 (market cap $33.79B). The key difference: Biogen Inc and DexCom, Inc. are close in size by market cap, and DexCom, Inc. is trading nearer its 52-week high, Biogen Inc nearer its low. Which is the better fit depends on your goals.

BIIBDXCM
Market Cap
$30.13B$33.79B
Sector
HealthHealth
52-Week High
$216.63$89.53
52-Week Low
$128.93$54.84
Enterprise Value
$37.20B$33.24B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Biogen Inc

Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.

Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.

DexCom, Inc.

DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.

The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.

Returns comparison

Trailing returns across standard periods

About Biogen Inc

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.

Read more on BIIB

About DexCom, Inc.

Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.

Read more on DXCM